NATCO PHARMA LTD WALK IN INTERVIEW ON 10 th JULY, 2021 @ HYDERABAD

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, Natco today has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.



Natco family currently consists of around 5000 employees, we are consistently ranked among fastest growing pharmaceutical companies in India. Natco is well recognized for its innovation in Pharmaceutical R&D.

At NATCO, we hold a leading market share in the oncology segment amongst Indian companies. Over the years, backed by our strong R&D capabilities, we have been able to launch many targeted therapy drugs. Gradually, we established ourselves as market leaders in the segment. The domestic oncology division deals with haemato-oncology and solid tumour products. As a result of our existing market position and product portfolio, we believe we are well positioned to capitalise on the expected growth in oncology therapeutic area.

We have a well-established presence in the domestic formulations market in gastro hepatology segment as well. In gastro hepatology therapeutic area, we have the leading market share in Hepatitis C drugs in India. We launched generic Sofosbuvir and its combinations for the treatment of Hepatitis C in India under the brands, Hepcinat Hepcinat LP, Velpanat and Natdac.

Further, we diversified our product portfolio in India by launching products in Cardiology and Diabetology therapeutic areas in 2017. This diversified strategy diminishes the risk associated with the dependence on any particular therapeutic area.

Our marketing and distribution network in India consists of a specialized field force, which enables us to increase the reach of our products in the domestic market. In addition, we also market our products directly to hospitals, which continue to be an important channel of distribution, in India, especially for oncology products. We believe that our extensive distribution network enables us to increase our market share across key therapeutic areas and sustain our leadership position.

Walk-in Drive for API Synthesis R&D / Process R&D / Chemical R&D

Company Name: Natco Pharma Limited

Eligibility: M.Sc. (Organic Chemistry) with 2019 / 2020 / 2021 passed out candidates (MALE) only.

Qualification: M.Sc (Organic Chemistry.

Work Experience: 2 - 3 yrs in API Synthesis R&D

Interview Date: 10.07.2021 @ 10.00 AM to 02.00 PM

Venue: Natco Pharma Limited, Natco Research Centre, B-13,

Industrial Estate, Sanath Nagar, Hyderabad - 500018.

Selection Process: Based on written test cum technical interview

Note: Interested Candidates, please carry your updated profile (with a passport size Photo) and experience candidates are requested to carry the latest Increment Letter.

For more updates follow www.globalpharmanews.co.in

Thank you for visiting my website, Visit again for latest pharma updates